Conference focuses on implants

ICOI to host its annual Winter Implant Symposium in Orlando

By ICOI Staff

Orlando and the surrounding Central Florida region is a favorite destination among travelers from around the globe. Join us there on Jan. 11-13 for the ICOI Winter Implant Symposium for a spectacular program designed by ICOI President Dr. Michael Pikos. Serving as our host hotel, the Orlando World Center Marriott offers amazing on-site amenities as well as a shuttle service to nearby amusement parks.

The theme for this meeting will be “Maxillary Arch Reconstruction: Single Tooth to Full Arch.” Scientific Program Chair Pikos, from Trinity, Fla., has assembled a talented group of experienced and enthusiastic, private practice and academic-based clinicians who will share their respective wealth of knowledge in a friendly and scientific environment.

The first day will feature a full afternoon podium devoted to our “Young Implantologists.” Quickly becoming a highlight of the ICOI meetings, this afternoon session on Thursday, Jan. 11, will showcase the fresh ideas and talents from our next generation of dental implantologists.

25th AAOMS Dental Implant Conference to continue its educational tradition

By AAOMS Staff

The American Association of Oral and Maxillofacial Surgeons (AAOMS) will host its 25th Dental Implant Conference — a premier dental implant educational event featuring an internationally renowned faculty of experts — from Nov. 30 to Dec. 2 in Chicago, Ill. More than 1,000 oral and maxillofacial surgeons, their staff and restorative dentists will gather to enhance their knowledge of dental implants, which offer patients a long-term solution to missing teeth. The event caters to the entire dental implant team.

By attending the three days of innovative research and procedural courses, participants can elevate their implant practice. Session topics — taught by more than 30 speakers — range from replacing congenital missing teeth to effectively applying digital technology in a practice.

Highlights of the preconference sessions and the intensive educational program will be the site of the 25th AAOMS Dental Implant Conference from Nov. 30 to Dec. 2. Photo/www.freeimages.com

*See ICOI, page A4
*See AAOMS, page A2
JOMS study: Botox can relieve jaw muscle pain

By JOMS Staff

Botox therapy can provide significant relief with only a mild risk for negative effects to patients with stubborn jaw pain in the muscles involved in chewing, according to a new retrospective study.

Chemically known as botulinum toxin A, Botox is a protein made from bacteria that, when injected, stops nerve signals that command muscles to contract—resulting in a months-long decrease in muscle activity. It has been used to treat conditions such as muscle spasms, facial wrinkles, migraines and excessive sweating.

According to the study published in the November issue of the Journal of Oral and Maxillofacial Surgery—the official journal of the American Association of Oral and Maxillofacial Surgeons (AAOMS)—botulinum toxin A injections also may have pain-relieving properties.

To determine the therapy’s safety and effectiveness in treating stubborn jaw muscle pain, researchers conducted a retrospective review of 16 patients. The patients underwent at least two Botox injection cycles for refractory masticatory myalgia—pain in the muscles used for chewing—that had not responded to other therapies.

The patients at the Department of Oral and Maxillofacial Surgery at Massachusetts General Hospital also had coexisting chronic pain disorders and were receiving other therapies and/or taking medications.

Nearly one-third of participants (30.6 percent) reported significant pain relief—indefinitely for 7.8 weeks on average, and 29.6 percent had no or minimal relief for 1.3 weeks on average. Among the participants, 14 percent reported at least one negative effect during the two injection cycles. Those who had significant pain relief had the largest number of adverse effects at 30.3 percent.

The most common side effect was a decrease in the size of the masticatory muscle, possibly due to blocked release of a chemical that activates muscles, the study states. However, all of the negative effects were minor and brief, and full recovery occurred within 16 weeks.

Simultaneous use of opioid pain relievers was a predictor of no or minimal relief. Of the participants, 36 percent were using a long-term opioid therapy. Long-term opioid use can result in opioid-induced hyperalgesia—a painful response to the medications—and having chronic pain disorders can lead to diminished effect of pain relievers, researchers wrote. “Together, these factors may result in poor outcome and response to therapy,” they said.

The authors of “Effectiveness, Safety, and Predictors of Response to Botulinum Toxin Type A in Refractory Masticatory Myalgia: A Retrospective Study” are all from the Department of Oral and Maxillofacial Surgery at Massachusetts General Hospital. David A. Keith, DMD, BDS, professor at Harvard School of Dental Medicine; Steven J. Scrivani, DDS, DMD, chief, Division of Oral and Maxillofacial Pain, Nicole Holland, DDS, MS, and Shehray N. Khawaja, BDS, MS, postgraduate Fellow at Harvard School of Dental Medicine.

The full article can be accessed at www.joms.org/article/50278-239177502186-7/fulltext.

About JOMS

The Journal of Oral and Maxillofacial Surgery is published by the American Association of Oral and Maxillofacial Surgeons to present to the dental and medical communities comprehensive coverage of new techniques, important developments and innovative ideas in oral and maxillofacial surgery. Practice-applicable articles help develop the methods used to handle dental and oral surgery, facial injuries and deformities, TMD disorders, oral and head and neck cancer, jaw reconstruction, anesthetics and analgesia. The journal also includes specifics on new instruments and diagnostic equipment, and modern therapeutic drugs and devices.

JOMS study: Botox can relieve jaw muscle pain

By JOMS Staff

Botox therapy can provide significant relief with only a mild risk for negative effects to patients with stubborn jaw pain in the muscles involved in chewing, according to a new retrospective study.

Chemically known as botulinum toxin A, Botox is a protein made from bacteria that, when injected, stops nerve signals that command muscles to contract—resulting in a months-long decrease in muscle activity. It has been used to treat conditions such as muscle spasms, facial wrinkles, migraines and excessive sweating.

According to the study published in the November issue of the Journal of Oral and Maxillofacial Surgery—the official journal of the American Association of Oral and Maxillofacial Surgeons (AAOMS)—botulinum toxin A injections also may have pain-relieving properties.

To determine the therapy’s safety and effectiveness in treating stubborn jaw muscle pain, researchers conducted a retrospective review of 16 patients. The patients underwent at least two Botox injection cycles for refractory masticatory myalgia—pain in the muscles used for chewing—that had not responded to other therapies.

The patients at the Department of Oral and Maxillofacial Surgery at Massachusetts General Hospital also had coexisting chronic pain disorders and were receiving other therapies and/or taking medications.

Nearly one-third of participants (30.6 percent) reported significant pain relief—indefinitely for 7.8 weeks on average, and 29.6 percent had no or minimal relief for 1.3 weeks on average. Among the participants, 14 percent reported at least one negative effect during the two injection cycles. Those who had significant pain relief had the largest number of adverse effects at 30.3 percent.

The most common side effect was a decrease in the size of the masticatory muscle, possibly due to blocked release of a chemical that activates muscles, the study states. However, all of the negative effects were minor and brief, and full recovery occurred within 16 weeks.

Simultaneous use of opioid pain relievers was a predictor of no or minimal relief. Of the participants, 36 percent were using a long-term opioid therapy. Long-term opioid use can result in opioid-induced hyperalgesia—a painful response to the medications—and having chronic pain disorders can lead to diminished effect of pain relievers, researchers wrote. “Together, these factors may result in poor outcome and response to therapy,” they said.

The authors of “Effectiveness, Safety, and Predictors of Response to Botulinum Toxin Type A in Refractory Masticatory Myalgia: A Retrospective Study” are all from the Department of Oral and Maxillofacial Surgery at Massachusetts General Hospital. David A. Keith, DMD, BDS, professor at Harvard School of Dental Medicine; Steven J. Scrivani, DDS, DMD, chief, Division of Oral and Maxillofacial Pain, Nicole Holland, DDS, MS, and Shehray N. Khawaja, BDS, MS, postgraduate Fellow at Harvard School of Dental Medicine.

The full article can be accessed at www.joms.org/article/50278-239177502186-7/fulltext.

About JOMS

The Journal of Oral and Maxillofacial Surgery is published by the American Association of Oral and Maxillofacial Surgeons to present to the dental and medical communities comprehensive coverage of new techniques, important developments and innovative ideas in oral and maxillofacial surgery. Practice-applicable articles help develop the methods used to handle dental and oral surgery, facial injuries and deformities, TMD disorders, oral and head and neck cancer, jaw reconstruction, anesthetics and analgesia. The journal also includes specifics on new instruments and diagnostic equipment, and modern therapeutic drugs and devices.

JOMS study: Botox can relieve jaw muscle pain

By JOMS Staff

Botox therapy can provide significant relief with only a mild risk for negative effects to patients with stubborn jaw pain in the muscles involved in chewing, according to a new retrospective study.

Chemically known as botulinum toxin A, Botox is a protein made from bacteria that, when injected, stops nerve signals that command muscles to contract—resulting in a months-long decrease in muscle activity. It has been used to treat conditions such as muscle spasms, facial wrinkles, migraines and excessive sweating.

According to the study published in the November issue of the Journal of Oral and Maxillofacial Surgery—the official journal of the American Association of Oral and Maxillofacial Surgeons (AAOMS)—botulinum toxin A injections also may have pain-relieving properties.

To determine the therapy’s safety and effectiveness in treating stubborn jaw muscle pain, researchers conducted a retrospective review of 16 patients. The patients underwent at least two Botox injection cycles for refractory masticatory myalgia—pain in the muscles used for chewing—that had not responded to other therapies.

The patients at the Department of Oral and Maxillofacial Surgery at Massachusetts General Hospital also had coexisting chronic pain disorders and were receiving other therapies and/or taking medications.

Nearly one-third of participants (30.6 percent) reported significant pain relief—indefinitely for 7.8 weeks on average, and 29.6 percent had no or minimal relief for 1.3 weeks on average. Among the participants, 14 percent reported at least one negative effect during the two injection cycles. Those who had significant pain relief had the largest number of adverse effects at 30.3 percent.

The most common side effect was a decrease in the size of the masticatory muscle, possibly due to blocked release of a chemical that activates muscles, the study states. However, all of the negative effects were minor and brief, and full recovery occurred within 16 weeks.

Simultaneous use of opioid pain relievers was a predictor of no or minimal relief. Of the participants, 36 percent were using a long-term opioid therapy. Long-term opioid use can result in opioid-induced hyperalgesia—a painful response to the medications—and having chronic pain disorders can lead to diminished effect of pain relievers, researchers wrote. “Together, these factors may result in poor outcome and response to therapy,” they said.

The authors of “Effectiveness, Safety, and Predictors of Response to Botulinum Toxin Type A in Refractory Masticatory Myalgia: A Retrospective Study” are all from the Department of Oral and Maxillofacial Surgery at Massachusetts General Hospital. David A. Keith, DMD, BDS, professor at Harvard School of Dental Medicine; Steven J. Scrivani, DDS, DMD, chief, Division of Oral and Maxillofacial Pain, Nicole Holland, DDS, MS, and Shehray N. Khawaja, BDS, MS, postgraduate Fellow at Harvard School of Dental Medicine.

The full article can be accessed at www.joms.org/article/50278-239177502186-7/fulltext.

About JOMS

The Journal of Oral and Maxillofacial Surgery is published by the American Association of Oral and Maxillofacial Surgeons to present to the dental and medical communities comprehensive coverage of new techniques, important developments and innovative ideas in oral and maxillofacial surgery. Practice-applicable articles help develop the methods used to handle dental and oral surgery, facial injuries and deformities, TMD disorders, oral and head and neck cancer, jaw reconstruction, anesthetics and analgesia. The journal also includes specifics on new instruments and diagnostic equipment, and modern therapeutic drugs and devices.

**SuperLine**

- Efficiency through Simplicity
- Predictability based on Clinical Research
American Academy of Implant Dentistry names its new honored fellows for 2017

By AAID Staff

The American Academy of Implant Dentistry (AAID) named six dentists from around the world to the coveted status of Honored Fellow at its recently concluded 66th Annual Conference. The honored fellow designation is awarded to those members of the AAID who, through their professional, clinical, research or academic endeavors, have distinguished themselves within implant dentistry. Named as AAID honored fellows were:

- George Arvanitis, DDS; Waterloo, Ontario, Canada
- Kirk Kalagiannis, DMD; Lyndhurst, N.J.
- Philip J. Kroll, DDS; Ventura, Calif.
- D. Timothy Pike, DDS; Rockville, Md.
- Dale Edward Spencer, DDS; Hickory, N.C.
- Dr. Atsushi Takahashi, Tokyo, Japan

About the AAID

Established in 1951, the AAID is the only dental implant organization that offers credentials recognized by state and federal courts as being bona fide. Its membership, which exceeds 6,000, includes general dentists, oral surgeons, periodontists and prosthodontists from across the United States and in more than 60 other countries.

Completion of all four certification programs also confers eligibility for ADIA fellowship credentialing. For information, visit www.adiaonline.org.

For full information on this symposium, visit our website at www.icoi.org.
Visit Us At ICOI ORLANDO
January 11–13 • Booth 505–507

PROCESS FOR PRF
CHOUKROUN PRF™ SYSTEM

Don’t You and Your Patients Deserve Choukroun’s Process PRF?

<table>
<thead>
<tr>
<th>The Choukroun Difference</th>
<th>Choukroun PRF</th>
<th>Other Companies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inventor of PRF</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>18 Years of Ongoing Research</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>World-Wide Distribution of Product and Lectures</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Continuous Modification of Techniques based on 1,000s of Clinical Case Reviews and Research</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>Continuous Review and Modifications of Centrifuge and Blood Collection Tubes</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td>On-Going Updates of How and Where to Use Liquid PRF and PRF Membranes based on clinical reviews and Research Available to Process for PRF Customers</td>
<td>YES</td>
<td>NO</td>
</tr>
</tbody>
</table>

Cost-effective and natural ways to regenerate tissues
- Save money for your practice and yourself using natural PRF in everyday practice as predictable barrier membranes, plugs for extraction sockets, and periodontal units
- Autogenous wound healing
- Improves bone graft stability
- Enhances bone density with a 30% increase
- Reduces inflammatory response
- Promotes faster healing
- Prevents soft tissue regeneration
- Improves the quality of bone

Learn More About the Benefits of PRF with our 1 Day Courses
for information and reservations go to www.hitecimplantsusa.com or call 800-452-0582

Cortical Cancellous Mineralized Bone

Neomem FlexPlus Native Porcine Peritoneum - Strong performance with a supple touch.

250-1000 Microns

Stronger - Neomem® FlexPlus has 3 times the suture pull out strength compared to Bio-Gide® and resorption time of 3-4 months.

Supple - Lack of memory means that Neomem® FlexPlus drapes and conforms to the defect site.

Better Initial Resorption Rate - Compared to Bio-Gide®, Neomem® FlexPlus initial in-vivo resorption profile suggests that Neomem® FlexPlus is more stable.

Less Inflammation - In-vivo testing also demonstrates that Neomem® FlexPlus produced a lower level of early inflammation than Bio-Gide® and Neomem® FlexPlus shows a lower level of a giant cell response.

Advantages
- High suture pull out strength
- Excellent draping
- Lower inflammation
- Easy handling
- 3-4 month resorption

Buy 5 Get 1 FREE!

Size         Your Price           Neomem Flex Plus
0.5cc        $40.00      15 x 20 mm  $82
1.0cc        $56.00      20 x 30 mm  $115
2.5cc        $83.00      30 x 40 mm  $165

Visit Us At ICOI ORLANDO
January 11–13
Booth 505–507

Dental Implant TECHNOLOGIES
www.hitecimplantsusa.com • 800-452-0582 • usaimplants@gmail.com
AAP and European Federation of Periodontology host a workshop on classification of periodontal and peri-implant diseases and conditions

By AAP Staff

In conjunction with the European Federation of Periodontology (EFP), the American Academy of Periodontology (AAP) hosted the World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions Nov. 9-11 at the Gleacher Center in Chicago. More than 100 international researchers, educators and clinicians gathered to review the latest literature and come to consensus on up-to-date guidelines for periodontal and peri-implant disease diagnosis and definition.

Participants conducted literature reviews, established case definitions and deliberated diagnostic considerations for the following topic areas: periodontal health and gingival diseases and conditions; periodontitis; developmental and acquired conditions and periodontal manifestations of systemic conditions; and peri-implant diseases and conditions. The inclusion of peri-implant diseases and conditions within periodontal disease classifications is a first, accommodating for what scientists and practitioners have come to understand about implant dentistry.

“Since the last World Workshop was held in 1999, periodontics has made notable advancements in the treatment and diagnosis of periodontal disease. The 2017 workshop intended to account for what we’ve learned in the last 18 years and help standardize the specialty’s definition of disease,” says Dr. Steven R. Daniel, president of the AAP. “Our collaboration with the EFP and periodontists from all over the world will work to positively shape the quality of patient care globally.”

The 2017 World Workshop is the second recent collaboration of the EFP and AAP. The groups’ joint workshop on periodontitis and systemic disease in 2012 was a major milestone in the specialty’s understanding of the perio-systemic link.

“After three years of preparation, it was rewarding to see many of the best and brightest in periodontics convene to accomplish the important task of updating and standardizing the definitions of periodontal and peri-implant diseases that will be used by dental professionals around the world. The contributions of the workshop’s expert participants will set the stage for periodontics’ expansive future,” said Dr. Jack Caton, co-chair of the event’s organizing committee.

Proceedings from the 2017 World Workshop on Periodontal Disease Classification will be published in both the AAP’s Journal of Periodontology and the EFP’s Journal of Clinical Periodontology in 2018.

About the AAP

The American Academy of Periodontology (AAP) represents more than 8,000 periodontists — specialists in the prevention, diagnosis and treatment of inflammatory diseases affecting the gums and supporting structures of the teeth, and in the placement of dental implants.
Let our new products tackle your toughest SURGICAL procedures

For Oral Surgery and Implantology

IA-400
Digital torque wrench

Surgical straight and contra-angle handpieces with or without Mini LED+

NEW Implantmed SI-101S with wireless foot pedal option, Osstell IQ option and LED powered motor option

Please visit us at the AAOMS in booth # 1310 to experience the latest in W&H surgical products!
You can also go to www.wh.com/nu for more information
‘Inspiring Imagination — Enhancing Health’: Registration opens for AO 2018 Annual Meeting

By AO Staff

If you’re interested in learning the newest techniques, observing demonstrations of the latest technologies and interacting in discussions about the current issues affecting implant dentistry, the Academy of Osseointegration (AO) 2018 Annual Meeting is a must-attend event — and registration is now open (http://meetings.osseo.org/2018/).

For the first time in its history, the Academy of Osseointegration will be hosting its annual meeting in Los Angeles from Feb. 28 to March 3 to put the spotlight on all the customary components, as well as new and interactive features.

“The academy’s 33rd annual meeting will feature a thrilling new format aimed at maximizing audience engagement and many exciting educational and networking opportunities,” said Dr. Joseph Kan, 2018 annual meeting program chair.

The new formats AO will be introducing will include:

• Concurrent surgical and restorative sessions with a new point-counterpoint format.
• “Lunch with the Masters” program.
• "Reflection Panel" as part of the closing session.

All sessions will assemble the foremost authorities in research and clinical practice from around the world who are on the cutting edge of scientific discovery in implant dentistry.

In addition to these new format changes to promote significantly more dialogue between attendees and presenters, AO will also be bringing back popular meeting favorites, including corporate forums and “Morning with the Masters” sessions. AO’s annual meeting will also continue to feature many opportunities to network with dental colleagues across all specialties and career stages from all corners of the globe.

Continuing AO’s tradition of supporting research and innovation, the oral clinical and oral scientific research and clinical innovations presentations will take place on Friday. With more than 250 abstracts and e-posters submitted for the 2018 annual meeting, attendees can get a first-hand look at a wealth of original and groundbreaking research conducted by its international implant dentistry member community.

For an additional registration fee, scientific content of the annual meeting can also include a number of options for hands-on workshops, all of which will take place on Feb. 28.

On the social side, the 2018 President’s Reception will be one of the most festive social gatherings ever assembled by AO. To be held in Microsoft Plaza within the L.A. Live area, just a stone’s throw from our headquarters hotel, this event complementary to registered attendees will provide an Oscar-themed evening filled with many surprises and an atmosphere of a miniature Times Square.

Registration fees for the annual meeting will include:

• Most scientific sessions (including TEAM Program and Laboratory Technician programs)
• Admission to the corporate forums and extensive exhibit hall
• Thursday’s Welcome Reception
• Friday’s President Reception
• Continental breakfasts
• Complimentary lunches in the exhibit hall
• Global networking opportunities

“This is also the perfect chance to bring your family to enjoy Disneyland, Universal Studios, visit the famous Rodeo Drive or attend a Lakers or Clippers game at the nearby STAPLES Center. With the heart of vibrant Los Angeles as the backdrop, AO looks forward to ‘Inspiring Imagination and Enhancing Health!’” Kan said.

Don’t delay in securing your attendance, making your hotel reservations or taking advantage of early bird rates. We recommend registering online, which is fast and easy. After Jan. 8, registration fees increase by $100. Don’t wait, register today at meetings.osseo.org/2018.
Neoss® Miami Symposium | April 20–21, 2018
Advancing Implant Dentistry from Ordinary to Extraordinary

Rainer H. Bergmann, DMD
Scott H. Froum, DDS
Jose R. Mellado, DMD & Giancarlo G. Romero, DDS, MS
Lars Senerby, DDS, PhD
Michael W. Brumm, DMD, AAACD
John A. Hodges, DDS
Anthony P. Randl, DDS
Chris Salierno, DDS
Chandur Wadhwnani, BDS, MSD
John A. Carollo, DMD
Jeffrey Kopman, DDS
Paul S. Rosen, DMD, MS
Program Chair

For more info go to: www.neoss.com/en/events/miami-2018
SALVIN® CytoSurg™
Non-Resorbable PTFE Membrane

- Sufficiently Firm To Protect The Defect – Supple Enough To Drape Over Surrounding Tissue
- Nominal Thickness Of 250 Microns
- Individually Packaged Sterile – 1 Membrane Per Box

Membranes Shown Actual Size
25mm x 30mm
12mm x 24mm

Space-Making Barrier In The Treatment Of Periodontal Defects
Textured Top Surface Provides Scaffold For Soft Tissue
Smooth Bottom Surface Against Bone For Easy Retrieval
Pore Size Less Than 0.3 Microns

SALVIN® CytoSurg™
Non-Resorbable PTFE Sutures

- Excellent Choice For Bone Grafting & Implant Procedures
- Smooth & Flexible - Not Fragile Or Brittle - So Knots Stay Tied
- Proprietary Monofilament Is Biologically Inert & Non-Cytotoxic
- Longer Length – All PTFE Sutures Now 24” Long

Black Needle For Higher Visibility & Less Glare
Super Sharp Needle Requires Less Force – Easier Suturing With Less Trauma

“Racetrack” Rather Than Zig-Zag Package
Little-To-No Package Memory For Excellent Handling And Secure Knotting

Ultra-Soft, Ultra-Smooth Suture Designed With Low Surface Porosity

Salvin Dental Specialties, Inc
Toll Free US & Canada 800-535-6566 • www.salvin.com
© 2017 Salvin Dental Specialties, Inc. All Rights Reserved.